A message from FARPE in Spain-
A clinical trial of a gene therapy product in the treatment of RP in France is currently being conducted at the University Hospital of Nantes (French Brexit).
They have contacted our federation to ask us to disseminate it, as they need more patients to continue this trial. In this way, we share information and ask for maximum dissemination.
A new group of patients is being recruited to test gene therapy treatment in patients with retinosis pigmentary caused by mutations in the PDE6B gene.
Patients eligible for research treatment must meet the following eligibility criteria:
— Having pigment retinosis due to mutations in the PDE6B gene
— To be between 13 and 17 years old
— Have a field of vision greater than 20 degrees.
For more details on eligibility criteria, you can access the international and public database http://ClinicalTrials.gov by clicking on the following link: https://www.clinicaltrials.gov/study/NCT03328130?term=coave%20therapeutics&checkSpell=false&rank=1
If you think you fit this profile, you or your ophthalmologist can contact the Nantes University Hospital – Professor Weber’s Department.
Contact Name: Fanny Billaud
By telephone: + 33 2 40 08 36 22
By email: Fanny.BILLAUD@chu-nantes.fr
In case you do not know your mutation, you can contact your ophthalmologist, who in turn can contact the teacher Weber directly by email: michel.weber@chu-nantes.fr
For more information, please contact us at farpe@retinosisfarpe.org or by calling: 915-32 07 07